Condition

DLBCL Transformed From Indolent Lymphoma (1)

Diffuse Large B-cell Lymphoma (1)

Follicular Grade 3 Lymphoma (1)

de Novo DLBCL (1)

Overall Status

Completed (1)

Sign in for free

Phase

phase 3 (1)

Sponsor

CTI BioPharma (1)

Collaborator

Intervention

gemcitabine + rituximab (1)

pixantrone + rituximab (1)

Study Documents

Intervention Type

drug (1)

Funder Type

Industry (1)

Study Type

Interventional (1)

follicular grade 3 lymphoma

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma Trial in Worldwide (Pixantrone +

Completed

Diffuse Large B-cell Lymphoma
+3 more

Pixantrone + Rituximab
Gemcitabine + Rituximab

Tucson, Arizona
+130 more

Oct 21, 2021